KUFMA DX SYRUP is a combination pharmaceutical formulation containing Phenylpropanolamine (NA) and Dextromethorphan Hydrobromide (NA), designed for the symptomatic relief of cough and nasal congestion associated with upper respiratory tract infections. Phenylpropanolamine acts as a sympathomimetic agent, exerting vasoconstrictive effects on the nasal mucosa, thereby reducing nasal congestion and facilitating easier breathing. Dextromethorphan Hydrobromide functions as a centrally acting antitussive, suppressing the cough reflex by acting on the medullary cough center without causing significant sedation or respiratory depression. This dual-action syrup provides effective relief from both cough and nasal obstruction, improving patient comfort and respiratory function. KUFMA DX SYRUP should be used according to the prescribed dosage and duration to minimize potential side effects such as increased blood pressure, dizziness, or gastrointestinal disturbances. It is contraindicated in patients with hypertension, cardiovascular diseases, or hypersensitivity to any of its components. Caution is advised when administering to children, pregnant or lactating women, and individuals on monoamine oxidase inhibitors (MAOIs) or other sympathomimetic drugs. Overall, KUFMA DX SYRUP offers a reliable therapeutic option for managing symptoms of upper respiratory tract infections under medical supervision.